<SEC-DOCUMENT>0001171843-23-003668.txt : 20230531
<SEC-HEADER>0001171843-23-003668.hdr.sgml : 20230531
<ACCEPTANCE-DATETIME>20230531161514
ACCESSION NUMBER:		0001171843-23-003668
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230531
FILED AS OF DATE:		20230531
DATE AS OF CHANGE:		20230531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		23981154

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_053123.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report: May 31, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38844</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59120 Loos, France</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9746; Form 20-F &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contents of this report on Form 6-K (including Exhibit 99.1) are
hereby incorporated by reference into the registrant&rsquo;s registration statement on Form F-3 (File No. 333-271312) and registration
statement on Form S-8 (File No. 333-271311) and related prospectuses, as such registration statements and prospectuses may be amended
from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or
reports subsequently filed or furnished. Information contained on, or that can be accessed through, any website included in Exhibit 99.1
is expressly not incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT LIST </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated May 31, 2023.</FONT></A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 31, 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><FONT STYLE="font-size: 16pt"><B>GENFIT
Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18.45pt"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 6.9pt">Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor
SRT-015 in acute liver disease</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18.45pt"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 7.1pt">Preclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in multi-system
disorders such as Acute-on-Chronic Liver Failure (ACLF)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18.45pt"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 6.95pt">First-in-Human study planned in the second half of 2024 to support a Proof-of-Concept study in ACLF
patients as early as 2025</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.25pt"></TD><TD STYLE="width: 18.45pt"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 16.7pt">No
                                            material impact on previously guided cash runway: company funding remains secured until the
                                            fourth quarter of 2024<SUP>1</SUP></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.2pt"></TD><TD STYLE="width: 18.5pt"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD>GENFIT&rsquo;s ACLF franchise now comprises 3 assets (VS-01, NTZ, SRT-015) based on differentiated mechanisms of action
                                                                                                               leveraging complementary pathways</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.7pt; color: #005478"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #005478">Lille (France); Cambridge (Massachusetts,
United States); Zurich (Switzerland); May 31, 2023 <FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005478">- GENFIT
(Nasdaq and Euronext: GNFT)</FONT><FONT STYLE="color: #232323">, </FONT><FONT STYLE="color: Black">a late-stage biopharmaceutical company
dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs, today announced
it has licensed the exclusive worldwide rights of ASK1 Inhibitor SRT-015 (injectable formulation in acute liver disease<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT>)
from Seal Rock Therapeutics, a Seattle, Washington (USA) based clinical stage company developing first-in-class and best-in-class kinase
inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ASK1 inhibition: a therapeutic strategy with multi-system benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASK1
inhibition has shown several potentially beneficial effects that may be relevant in ACLF, such as blocking LPS (lipopolysaccharide) associated
hyperinflammatory response, reducing the ROS (Reactive Oxygen Species)-related immune response, reducing apoptosis, reducing release
of the proinflammatory cytokines, reducing fibrosis, and protecting macrophage mitochondrial function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Multi-organ benefits have been observed in several animal models and
clinical trials <FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><SUP>1</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Based
on current assumptions, excluding exceptional events and in particular, potential milestone payments, which GENFIT would receive, should
the ELATIVE&reg; study be successful</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><SUP>2</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>GENFIT
acquired the rights of SRT-015 for use in liver disease in which injectable therapy is intended to be administered for a </I></FONT><I>period
of 21 consecutive days or less, including the management of ACLF during such a period</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><SUP>3</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>ASK1
inhibition: a therapeutic strategy with multi-system benefits: Journal of Molecular Medicine (2020)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="width: 576px; height: 14px"></TD><TD STYLE="text-align: right; width: 50%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I><IMG SRC="header.jpg" ALT=""></I></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.7pt"></TD><TD STYLE="width: 17.65pt"><FONT STYLE="color: #232323">&ndash;</FONT></TD><TD>In kidney diseases, ASK1 modulation limits renal inflammation, apoptosis and fibrosis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.7pt"></TD><TD STYLE="width: 17.65pt"><FONT STYLE="color: #232323">&ndash;</FONT></TD><TD>In liver diseases, ASK1 modulation prevents hepatocyte death, inflammation and fibrosis</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.7pt"></TD><TD STYLE="width: 17.65pt"><FONT STYLE="color: #232323">&ndash;</FONT></TD><TD>In brain disorders, ASK1 modulation limits neurodegeneration</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.7pt"></TD><TD STYLE="width: 17.65pt"><FONT STYLE="color: #232323">&ndash;</FONT></TD><TD>In inflammatory diseases, ASK1 modulation limits damaging immune responses, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.7pt"></TD><TD STYLE="width: 17.65pt"><FONT STYLE="color: #232323">&ndash;</FONT></TD><TD>In cardiopulmonary disease, ASK1 modulation slows the onset of heart failure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005478">Pascal
Prigent, CEO of GENFIT</FONT> <FONT STYLE="color: #232323">commented:</FONT> &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>We
are excited to be announcing this licensing deal which marks an additionalmilestone in the execution of our development strategy in liver
diseases with high unmet medical needs. ACLF is a complex disorderthat will likely require the combination of different approaches and
with this acquisition, we continue to strengthen our leadership in this indication. We nowhave a unique portfolio of three differentiated
clinical stage programs in ACLF. Considering its liver- centric activity, the potential for multi-organ benefits and the breadth of evidence
supporting further development in ACLF, we strongly believe in the potential of SRT-015.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Under the agreement, Seal Rock
Therapeutics is eligible for payments up to &euro;100 million, including regulatory, clinical, and commercial milestone payments, plus
tiered royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other assets in GENFIT&rsquo;s ACLF franchise</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In ACLF, whose market
size has been estimated by IQVIA to reach almost $4 billion in the US and in the five main European countries by 2030, GENFIT is developing
two other assets: VS-01 and NTZ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.7pt">-&nbsp;&nbsp;<B>VS-01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VS-01 is currently being evaluated
in the international UNVEIL-IT&trade; Phase 2, open-label, randomized, controlled, multi-center, proof of concept study to assess its
efficacy, safety, and tolerability in addition to standard of care (SOC), compared to SOC alone, in adult patients with ACLF grades 1
and 2 and ascites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IND (Investigational New Drug)
was in effect as of April 17, 2023, and the first patient is expected to be screened and enrolled in the Phase 2 trial in the coming days.
It is planned that approximately 60 adult patients with ACLF grades 1 and 2 will be enrolled in this trial. Patients will be randomized
in a 1:1 ratio to receive either daily intraperitoneal administration of VS-01 over 4 days on top of SOC (active treatment group) or SOC
alone (control group).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="width: 576px; height: 14px"></TD><TD STYLE="text-align: right; width: 50%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary objective of the study is to measure efficacy using the
Chronic Liver Failure Consortium (CLIF-C) ACLF<FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT> score at day 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data expected to be available in
the first half of 2024 should support preparation of further testing of efficacy. Given the high unmet need in this indication andthe
Orphan Drug Designation obtained from the US Food and Drug Administration for VS-01, it is expected that the program qualifies for some
of the expedited regulatory pathways provided by health authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.7pt">-&nbsp;&nbsp;<B>NTZ</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 5.25pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preliminary data from two Phase 1 studies recently conducted in
subjects with renal impairment and subjects with hepatic impairment supported a favorable safety and tolerability profile. Taken
together, safety and pharmacokinetic results, as well as exploratory pharmacodynamic data, support further clinical development of
NTZ in patients with ACLF, and a Phase 2a proof of concept study with NTZ in patients with ACLF grades 1 and 2 is currently under
discussion with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #005478"><B>ABOUT ACLF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acute-on-Chronic
Liver Failure is a rare, life-threatening, but potentially reversible condition of varied etiology. ACLF is recognized clinically as a
syndrome, globally defined by multi-organ dysfunction and failure in patients with chronic liver disease or liver cirrhosis and high short-term
mortality within a period of 28 to 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patients with cirrhosis may initially be compensated. With progression,
many patients will go on to have acute decompensation of cirrhosis characterized by the rapid development of complications such as ascites,
hepatic encephalopathy (HE), gastrointestinal hemorrhage, or bacterial infection, which are very common causes of hospitalization. On
admission, approximately 30% of these </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP> <FONT STYLE="color: #232323"><I>The EASL-CLIF Consortium
is a network of more than a hundred of European University Hospitals which carry out clinical investigations of the EASL-CLIF Chair aimed
at performing large observational, pathophysiological and therapeutic studies to increase our understanding of Chronic Liver Failure
and to improve the management of patients with cirrhosis.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="width: 576px; height: 14px"></TD><TD STYLE="text-align: right; width: 50%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I><IMG SRC="header.jpg" ALT=""></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">patients will develop liver and/or other organ failure(s) (i.e, brain,
kidneys, cardiovascular and respiratory) and will be considered as having ACLF.<FONT STYLE="font-size: 10pt"><SUP>5 6 7 8 9</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.35pt 0pt 5.25pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GENFIT is a late-stage
biopharmaceutical company dedicatedto improving the lives of patients with liver diseases characterized by high unmet medical needs. GENFIT
is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today
GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Its R&amp;D pipeline
covers six therapeutic areas via seven programs which explore the potential of differentiated mechanisms of action, across a variety of
development stages (pre-clinical, Phase 1, Phase 2, Phase 3). These diseases are acute on-chronic liver failure (ACLF), hepatic encephalopathy
(HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD), organic acidemias (OA) and primary biliary cholangitis (PBC). Beyond therapeutics,
GENFIT&rsquo;s pipeline also includes a diagnostic franchise focused on NASH and ACLF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GENFIT has facilities
in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global
Select Market and on compartment B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one
of GENFIT&rsquo;s largest shareholders and holds 8% of the company&rsquo;s share capital. www.genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #005478"><B>ABOUT SEAL ROCK THERAPEUTICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Seal Rock Therapeutics is a privately held, clinical stage company
based in Seattle focused on developing first-in-class and best-in-class treatments for severe diseases with limited or no available therapies.
Seal Rock is led by an experienced management team with a track record of successful drug discovery, development, and commercialization.
The company&rsquo;s clinical-stage lead</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP> <FONT STYLE="color: #3B3B3A"><I>Arroyo V et al., J Hepatol,
2015, 62(1 Suppl), S131 -S143</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Malik
R et al., J Hepatol, 2009, 51(3), 426 -9</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Olson
JC et al., Hepatology, 2011, 54(5), 1864 -72</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>8</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Jalan
R et al., J Hepatol, 2012, 57(6), 1336 -48</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>9</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Wlodzimirow
KA et al., Liver International, 2013, 33(1), 40 -42</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="width: 576px; height: 14px"></TD><TD STYLE="text-align: right; width: 50%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> product candidate, SRT-015, is a highly optimized, first-in-class ASK1 inhibitor. Seal Rock is
also developing preclinical-stage brain-penetrant ASK1/LRRK2 dual kinase inhibitors for the treatment of neurodegenerative conditions
such as Parkinson&rsquo;s disease and ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #005478"><B>GENFIT FORWARD
LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains certain forward-looking statements
with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to the
potential, efficacy, safety, tolerability, regulatory milestones and development and data timelines for SRT-015, VS-01 and NTZ, and the
overall market size and prevalence of ACLF. The use of certain words, including &ldquo;consider&rdquo;, &ldquo;contemplate&rdquo;, &ldquo;think&rdquo;,
&ldquo;aim&rdquo;, &ldquo;expect&rdquo;, &ldquo;understand&rdquo;, &ldquo;should&rdquo;, &ldquo;aspire&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;targeted&rdquo;, &ldquo;anticipated&rdquo;, &ldquo;believe&rdquo;, &ldquo;wish&rdquo;, &ldquo;may&rdquo;, &ldquo;could&rdquo;,
&ldquo;allow&rdquo;, &ldquo;seek&rdquo;, &ldquo;encourage&rdquo; or &ldquo;have confidence&rdquo; or (as the case may be) the negative
forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking
statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company&rsquo;s
management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual
results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties
include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, cost
of, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities in the
United States, Europe and worldwide, of our drug and diagnostic candidates, exchange rate fluctuations, potential synergies related to
the acquisitionof Versantis, our capacity to integrate its assets, develop its programs and our continued ability to raise capital to
fund our development, as well as those risks and uncertainties discussed or identified in the Company&rsquo;s public filings with the
AMF, including those listed in Chapter 2 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s 2022 Universal Registration
Document filed with the AMF on April 18, 2023, which is available on the Company&rsquo;s website (www.genfit.com) and on the website
of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;)
including the Company&rsquo;s 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023. In addition, even if the Company&rsquo;s
results, performance, financial conditionand liquidity, and the development of the industry in which it operates are consistent with
such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements
speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any
obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="width: 576px; height: 14px"></TD><TD STYLE="text-align: right; width: 50%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #005478"><B>CONTACT</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt; color: #232323">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">GENFIT</FONT>
| Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #232323">Tel : + 33 3 20 16 40 0</FONT><FONT STYLE="color: Black">0
| investors@genfit.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">PRESS
RELATIONS</FONT> <FONT STYLE="color: Black">| Media</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Stephanie BOYER &ndash; Press relations
| Tel : + 33 3 20 16 40 00 | stephanie.boyer@genfit.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 14px; width: 576px"></TD>
  <TD STYLE="text-align: right; width: 50%">6</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 header.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A=F]I92P@
M2V5V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S4V  "2
MD@ "     S4V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#(S.C U.C,Q(# V.C4X.C,Y #(P,C,Z,#4Z
M,S$@,#8Z-3@Z,SD   !3 &$ =@!O &D 90 L "  2P!E '8 :0!N    _^$+
M(&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D
M9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD
M,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P,C,M,#4M,S%4,#8Z-3@Z,SDN
M-38P/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M
M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX\<F1F.FQI/E-A=F]I92P@2V5V:6X\+W)D9CIL:3X\+W)D9CI397$^
M#0H)"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&
M/CPO>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K
M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5
M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*
M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@ M ,6 P$B  (1 0,1 ?_$ !\   $% 0$!
M 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$"
M P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G
M*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%
MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35
MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M $9'7L]>+?!S'_"8W>/^?!__ $9'7M->;B?XA[6#_A!1117,=@4444 %%%%
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M0 YB0JHP\U".<CI^-(%$I7;(!L&%!'7\:$\R/>R2;N.-O.:12CA@?W98]2*
M'JYVR&6-6"'&2>1]*?%&S1L8=Q<MZ]OI48)C94(64']:<JAYB8L@A3\H/0T
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M;&X(I/;'3-:NO:>+>Y$T6-DG./0UE [ADG!Q5F8WDKTSDT%3G /3M2X''-
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MP(5;..3BKMOIG(:=L^U(17M[>6\D"J,*>K=,5W&D6%O96@6'EC]YO6L% L8
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M&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M $9'7MM>/?"6-4\6W1 _Y<7_ /1B5[#7G5U:9[&&=Z84445@=(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A=F]I92P@
M2V5V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S S  "2
MD@ "     S S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M);I K Y#$?ZIL<MU&3UH Z=/%FBOK)TM;MC<B8V^[R)/*,P7<8A+M\LN!D[
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M ++1K?\ S-'_ &,MG_[+111+K\__ &X*7V?^W?\ W$=IX(_Y&KQE_P!A-?\
MT6*[.BBO0H_!]_YGQN9?[Q\H_P#I*"BBBMCSPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
